Articles

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

Mayo Clinic, Rochester, MN
H. Lee Moffitt Cancer Center, Tampa, FL
Helen F Graham Cancer Center, Newark, DE
Indiana University Health Center for Cancer Care, Goshen, IN
Immunomedics, Morris Plains, NJ
Immunomedics, Morris Plains, NJ
Immunomedics, Morris Plains, NJ;Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA
Vol. 99 No. 11 (2014): November, 2014 https://doi.org/10.3324/haematol.2014.112110